Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Dyne Therapeutics Inc.

Dye & Durham ( ($TSE:DND) ) has shared an update. Dye & Durham said the Toronto Stock Exchange has deferred its decision on accepting the company’s...

Dye & Durham’s Rights Plan Faces TSX Deferral Amid Ongoing Sales Process

Dynagreen Environmental Protection Group Co., Ltd. Class H ( ($HK:1330) ) has provided an announcement. Dynagreen Environmental Protection Group re...

Dynagreen Sees Minimal Bond Conversion as Most Convertible Issue Remains Outstanding

J.P. Morgan analyst Tessa Romero maintained a Hold rating on Dyne Therapeutics today and set a price target of $16.00. Romero covers the Healthcare...

J.P. Morgan Reaffirms Their Hold Rating on Dyne Therapeutics (DYN)

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Palladyne AI Corp (PDYN – Research Report) and Shi...

Analysts’ Opinions Are Mixed on These Technology Stocks: Palladyne AI Corp (PDYN) and Shift4 Payments (FOUR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jade Biosciences (JBIO – Research Report) and Dyne T...

Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO) and Dyne Therapeutics (DYN)

This ETF spotlights three ETFs with Outperform ratings and significant upsides, based on TipRanks’ AI analyst’s assessment.


Current Quarter	$-0.74	Next Quarter	$-0.75
Current Year	$-2.94	Next Year	$-2.74
QoQ Growth	-1.4%	YoY Growth	+6.8%
3Y EPS CAGR	N/A	Target Price	$38.19
Consensus	Buy	Upside	+108.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DYN	$18.31	+0.83%	750.85K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DYN	$18.31	+0.8%	750.85K
3
4
5
6

DYN

DYN

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Dyne Therapeutics Inc. Data in Excel

Get Dyne Therapeutics Inc. Data in Excel